Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

Recent clinical developments in non-Hodgkin lymphoma emphasize a transition toward personalized, less toxic treatment paradigms. In Diffuse Large B-Cell Lymphoma, the integration of novel agents like antibody-drug conjugates and bispecific antibodies challenges traditional chemotherapy standards, with ongoing research into MRD-stratified de-escalation strategies. The discussion highlights the emergence of non-covalent BTK inhibitors and BCL-2 inhibitors, which offer durable responses in relapsed or refractory settings while requiring careful management of unique toxicities such as cytokine release syndrome and photosensitivity. Furthermore, the shift in mantle cell lymphoma management moves away from universal transplantation toward biological stratification, particularly for high-risk patients with TP53 mutations. Beyond therapeutic efficacy, the focus extends to comprehensive survivorship care, underscoring the necessity of multidisciplinary support to address long-term anxiety, primary care integration, and the evolving needs of patients achieving sustained remission.